Cantor Fitzgerald and Citigroup reiterate positive ratings for Sagimet Biosciences
1 report, 1 independent
Updated Tue 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald and Citigroup reiterated positive ratings for Sagimet Biosciences on November 10, 2026. Sagimet Biosciences is expected to announce its Q3 2026 results before the market opens on November 12th.
From tickerreport.com
Why it matters
The reiterated ratings affirm positive sentiment toward Sagimet Biosciences. Analysts expect the company to post ($0.25) earnings per share and $0.17 million in revenue for the third quarter.
From tickerreport.com
Who's involved
- Cantor FitzgeraldRestated an "overweight" rating on shares of Sagimet Biosciences.
- CitigroupReiterated a positive rating for Sagimet Biosciences.
Keep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
Citigroup
American investment bank and financial services corporation
Related events
- MarketBeat reported the stock's average rating while Citigroup reiterated a buy rating and Cantor Fitzgerald restated an overweight rating for Beta Technologies.
- Citigroup and Cantor Fitzgerald issued rating updates, while disclosures were required by the SEC.
- Morgan Stanley reaffirmed an underweight rating and Citigroup restated a sell rating on Handelsbanken, reported by MarketBeat.
- Agilysys CEO Ramesh Srinivasan sold significant company shares, with the transaction disclosed via filings with the SEC, concurrent with a rating from Cantor Fitzgerald.
- Cantor Fitzgerald reiterated its 'overweight' rating on Oracle stock on June 11, 2026.